Chemotherapy for advanced urothelial cancer: end of the beginning?

Affiliations

¹ University of Virginia Cancer Center, Department of Medicine, University of Virginia, Box 800716, 6261 Multi-Story Building, Charlottesville, VA 22908, USA. Electronic address: dreicer@virginia.edu.

Comment

Robert Dreicer. Lancet Oncol. 2017 May.

. 2017 May;18(5):567-569.

doi: 10.1016/S1470-2045(17)30241-3. Epub 2017 Apr 4.

¹ University of Virginia Cancer Center, Department of Medicine, University of Virginia, Box 800716, 6261 Multi-Story Building, Charlottesville, VA 22908, USA. Electronic address: dreicer@virginia.edu.

No abstract available

Comment on

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J. García-Donas J, et al. Lancet Oncol. 2017 May;18(5):672-681a. doi: 10.1016/S1470-2045(17)30242-5. Epub 2017 Apr 4. Lancet Oncol. 2017. PMID: 28389316 Clinical Trial.